Clinical trials: Metabolism and Elimination
Healthy
A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)
The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants.
- Trial name
- NCT06777602
- Testing
- [14C] MK-5475
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered [14C] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease…
- Trial name
- AME (NCT02986100)
- Testing
- C-14 labeled Rucaparib, Rucaparib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- pharmaand GmbH
Healthy Subjects
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of [14C] tavapadon.
- Trial name
- NCT04241393
- Testing
- Tavapadon tablet, Tavapadon [14C] suspension
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Solid Tumor
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
This is a single sequence 2-period open label study in participants with advanced solid tumors. The purpose of Period 1 of this study is to assess the mass balance to determine drug-related entities present in circulation and…
- Trial name
- NCT06308263
- Testing
- Tuvusertib [14C]Tuvusertib microtracer, Tuvusertib, Tuvusertib + [14C]Tuvusertib microdose bolus injection
- Where
- Hungary
- Volunteers
- 12 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Pain
A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
- Trial name
- NCT06886269
- Testing
- 14C-VX-993
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Lymphoblastic Leukemia, Acute Leukemias
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
- Trial name
- NCT07295951
- Testing
- 14C-bleximenib, bleximenib
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931
Study to Assess the Absorption, Metabolism and Excretion of [14C]AZD8931 after a Single-Dose Oral Administration
- Trial name
- NCT01284595
- Testing
- [14C] AZD8931
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin
The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.
- Trial name
- NCT02791035
- Testing
- Oral administration of Ipragliflozin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Advanced Malignancies, Solid Tumors
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
- Trial name
- NCT00426140
- Testing
- Patupilone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Enteritis
A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects
To obtain absorption, metabolism and excretion data for parent drug and any metabolites.
- Trial name
- NCT02440633
- Testing
- 14C-OPS-2071
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305
The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.
- Trial name
- NCT00689247
- Testing
- AZD1305
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
The purpose of this study is to evaluate the effect of treatment with CCX140-B on urinary albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to study the safety and efficacy of the medication…
- Trial name
- NCT01440257
- Testing
- CCX140-B
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amgen
ALK-POSITIVE NSCLC
The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] Ensartinib in healthy Chinese male subjects.
- Trial name
- NCT03804541
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Hyperphagia, Prader-Willi Syndrome
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101.
- Trial name
- HERO (NCT06828861)
- Testing
- ARD-101
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 68 people
- Sponsor
- Aardvark Therapeutics, Inc.
Cardiovascular Disease
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects
Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration
- Trial name
- NCT04686591
- Testing
- AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL), [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects
This single centre, open-label, non-randomised, single period, single-dose study in healthy male subjects was designed and conducted to assess the mass balance recovery, PK, metabolite profile and metabolite identification of…
- Trial name
- NCT05320861
- Testing
- [14C]SJP-0008
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Healthy Volunteers
Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects
The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of [14C]varespladib methyl.
- Trial name
- NCT01359605
- Testing
- varespladib methyl
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Anthera Pharmaceuticals
Obesity, Bariatric Surgery
Impact of Weight Loss After a Bypass Surgery on Renal Hemodynamic Under Stress Conditions
The sympathetic nervous (SNS) and the renin angiotensin aldosterone system (RAS) have a direct impact on renal hemodynamic, hormonal secretion and vasoactive peptide.
- Conditions
- Obesity, Bariatric Surgery, Blood Pressure
- Trial name
- OBBYSS (NCT02218112)
- Testing
- bariatric surgery (gastric bypass)
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Healthy Subjects, Pharmacokinetics of ASP3652
A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652
This study measures how much of the trial drug enters the body and how long it takes for the body to remove it via the feces and urine.
- Trial name
- NCT02046798
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Cholestasis
Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat
Absorption, metabolism and excretion of linerixibat have been studied in previous clinical trials. However, no dedicated clinical studies of drug absorption, metabolism, and excretion have been conducted for linerixibat.
- Trial name
- NCT03992014
- Testing
- Linerixibat tablet, [14C]-linerixibat intravenous infusion, Linerixibat oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline